Evidence map›Paper›PMID 36757205›Full record

ArticleJournal of virology2023

Immunization of Mice with Virus-Like Vesicles of Kaposi Sarcoma-Associated Herpesvirus Reveals a Role for Antibodies Targeting ORF4 in Activating Complement-Mediated Neutralization.

Alex K Lam, Romin Roshan, Wendell Miley, Nazzarena Labo, James Zhen, Andrew P Kurland, Celine Cheng, Haigen Huang, Pu-Lin Teng, Claire Harelson and 8 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Alex K LamDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.ORCID 0000-0003-2879-719X
Romin Roshan *AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Wendell Miley *AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Nazzarena Labo *AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
James ZhenDepartment of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Andrew P KurlandDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Celine ChengDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Haigen HuangDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Pu-Lin TengDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Claire HarelsonDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Danyang GongDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Ying K TamAcuitas Therapeutics, Vancouver, British Columbia, Canada.
Caius G RaduDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Marta EpeldeguiDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Jeffrey R JohnsonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Z Hong ZhouDepartment of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, California, USA.ORCID 0000-0002-8373-4717
Denise WhitbyAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Ting-Ting WuDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
University of California, Los Angeles · USFrederick National Laboratory for Cancer Research · USIcahn School of Medicine at Mount Sinai · USAcuitas Therapeutics (Canada) · CA

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert Damoiseaux · 1985 to 2026
$134.5M
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZACK, JEROME A. · 1991 to 2018
$39.9M
Study of Hearing and Balance in Middle Aged and Aging Men and Women in the MACS-WIHS Combined Cohort StudyU01HL146333 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Roger Detels, Matthew James Mimiaga · 2019 to 2026
$32.2M
In situ atomic structures of the Kaposi's sarcoma-associated herpesvirus portal-terminase complex and glycoproteinsR01DE025567 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WU, TING-TING, ZHOU, Z HONG · 2016 to 2024
$4.0M
Interdisciplinary Training in Virology and Gene TherapyT32AI060567 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WU, TING-TING · 2004 to 2018
$3.4M
Regulation of mRNA export during gammaherpesvirus infectionR01DE028774 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WU, TING-TING · 2019 to 2023
$2.0M
NCATS NIH HHS UL1 TR001881NCI NIH HHS 75N91019D00024NCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INCI NIH HHS P30 CA016042NHLBI NIH HHS U01 HL146333NIAID NIH HHS P30 AI028697NIAID NIH HHS T32 AI060567NIDCR NIH HHS R01 DE025567NIDCR NIH HHS R01 DE028774
6 · The paper itself

Abstract

Infection by Kaposi sarcoma-associated herpesvirus (KSHV) can cause severe consequences, such as cancers and lymphoproliferative diseases. Whole inactivated viruses (WIV) with chemically destroyed genetic materials have been used as antigens in several licensed vaccines. During KSHV productive replication, virus-like vesicles (VLVs) that lack capsids and viral genomes are generated along with virions. Here, we investigated the immunogenicity of KSHV VLVs produced from a viral mutant that was defective in capsid formation and DNA packaging. Mice immunized with adjuvanted VLVs generated KSHV-specific T cell and antibody responses. Neutralization of KSHV infection by the VLV immune serum was low but was markedly enhanced in the presence of the complement system. Complement-enhanced neutralization and complement deposition on KSHV-infected cells was dependent on antibodies targeting viral open reading frame 4 (ORF4). However, limited complement-mediated enhancement was detected in the sera of a small cohort of KSHV-infected humans which contained few neutralizing antibodies. Therefore, vaccination that induces antibody effector functions can potentially improve infection-induced humoral immunity. Overall, our study highlights a potential benefit of engaging complement-mediated antibody functions in future KSHV vaccine development.

Indexed as

Antibodies, NeutralizingHerpesvirus 8, HumanAnimalsHerpesviridae InfectionsHumansMiceOpen Reading FramesVaccinationViral ProteinsAntibodies, NeutralizingViral Proteinsantibody functioncomplementKSHVneutralizing antibodiesvaccine

Identifiers

PMID36757205
PMCPMC9972917
OpenAlexW4319657209

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.